Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trial

摘要: Objective To determine if minocycline therapy improved skin thickness in early, diffuse systemic sclerosis (SSc) by ≥30%, a level of improvement unlikely to occur the natural history disease as determined recent controlled trials. Methods Subjects with SSc ≤5 years' duration were treated oral for 1 year. The primary outcome measure was modified Rodnan score (MRSS). Results Of 36 subjects initially enrolled, 31 returned at least followup visit and included analysis (modified intent-to-treat analysis). group consisted 23 women 8 men, mean age 51.7 years (range 26–82 years) 23.5 months 6–60 months). MRSS entry 22.7 12–43), final it 18.6 2–48). There no statistically significant difference change scores between minocycline-treated previously reported D-penicillamine (D-Pen) trial. In addition, when adjusted duration, comparison trial (including all active each time point) D-Pen showed treatment effect. Fourteen did not complete 12 treatment; 10 them withdrew due progression. Disease significantly shorter noncompleters than completers (P < 0.03). Conclusion The degree similar that expected course this disease. Based on these data, is an effective SSc.